Flo Health has pulled in $200mn from private equity firm General Atlantic to become the first fully digital female health start-up valued at more than $1bn as investors tap into the growing market for fertility and menopause products. The world’s largest period and fertility tracker by user numbers will put the funding towards building features such as symptom analysis for the estimated 450mn women worldwide, according to McKinsey, who experience perimenopausal or menopausal symptoms annually.
It expects its revenues from subscriptions, which vary by region but start at £4.99 monthly in the UK, to exceed $200mn this year. Flo is the latest start-up seeking to tap into the growing market for menopause and perimenopause therapeutics. The sector has grown rapidly in recent years as discussions about menopause have become more mainstream.